JCR Pharmaceuticals Q1 FY2027 Earnings Deep Dive Report

JCR Pharmaceuticals Co., Ltd. (Securities Code: 4552), a specialty pharmaceutical company focused on rare digestive and genetic diseases, has announced its consolidated financial results for the first quarter (Q1) of the fiscal year ending March 31, 2027. This report provides a multi-faceted analysis of the company's current performance highlights, sales trends of key products, progress in high-potential pipelines, and its mid-to-long-term growth trajectory, based on the published earnings presentation materials.

---

1. Q1 FY2027 Performance Highlights: A Structure of Aggressive R&D Investment and Revenue Growth Amidst Operating Losses

For the first quarter of the fiscal year ending March 31, 2027, JCR Pharmaceuticals reported consolidated net sales of 9,700 million yen (+13.2% YoY), an operating loss of 2,103 million yen (compared to a 606 million yen loss in the same period last year), an ordinary loss of 2,084 million yen (compared to a 749 million yen loss), and a quarterly net loss attributable to owners of the parent of 1,907 million yen (compared to a 546 million yen loss).

While the company achieved steady year-on-year revenue growth this quarter, profitability was impacted by an expanded operating deficit. The primary factors behind this financial structure are as follows:

• Revenue Growth Drivers : Despite the impact of drug price revisions on existing major pharmaceuticals, a significant increase in contract revenue to 1,474 million yen (+1,278.8% YoY) drove the overall top-line growth.
• Operating Profit Factors : The primary driver is the sharp increase in R&D expenses . R&D costs for the quarter reached 5,888 million yen (+75.9% YoY), pushing the R&D-to-sales ratio to 60.7% (up from 39.1% in the same period last year). This is attributed to the concentration of global clinical trial costs in this quarter and the acceleration of trials at a pace exceeding initial plans, alongside increased CRO (Contract Research Organization) related expenses.
• Improvement in Cost of Sales : The cost of sales ratio improved by 4.3 percentage points to 23.2% (from 27.5% in the same period last year). Even on a product-mix basis excluding contract revenue, the cost of sales ratio showed an improving trend at 26.1% (from 27.7%).

The following slide illustrates the overall consolidated profit and loss for Q1 FY2027.

[Slide Commentary: Significance of Q1 Consolidated Earnings Overview]

This slide clearly indicates that JCR Pharmaceuticals' current management strategy is in an 'acceleration phase for R&D investment.' While the growth of general administrative expenses within SG&A was contained at +5.6% YoY (3,665 million yen), the substantial increase in R&D spending highlights a commitment to prioritizing upfront investment to maximize pipeline value. Furthermore, R&D expenses before deductions for co-development partner contributions reached 6,523 million yen (+85.4% YoY), confirming that large-scale clinical trials and research are progressing with financial support from strategic partners.

---

2. Detailed Analysis by Product and Revenue Source: Trends in Existing Key Drugs and New Licensing Income

An analysis of the Q1 revenue breakdown (Total: 9,700 million yen) by product and source reveals structural changes and specific individual factors:

1. Growject® (Human Growth Hormone)
   • Sales: 3,744 million yen (-16.7% YoY, 21.4% of annual target)
   • Status: Sales declined year-on-year due to the drug price revision in April 2026. Although quarterly results fell short of the plan, market share remains high, and the company aims to achieve its full-year target.
2. Izcargo® (Enzyme Replacement Therapy for MPS II)
   • Sales: 1,669 million yen (+6.8% YoY, 24.1% of annual target)
   • Status: As the flagship product utilizing the proprietary blood-brain barrier (BBB) penetration technology "J-Brain Cargo®," the number of domestic patients treated is increasing steadily (94 cases as of Q1). Sales are following a consistent upward trend.
3. Stem Cell Products, Dialysis, and Other Biosimilars
   • Temcell® HS Inj. : Sales of 721 million yen (-14.6% YoY). Despite changes in the competitive environment, performance remains generally in line with the plan.
   • Renal Anemia Treatment (Darbepoetin Alfa BS Inj. "JCR", etc.) : Sales of 748 million yen (-16.6% YoY). Sales are recorded according to supply plans to distributors (e.g., Kissei Pharmaceutical).
   • Agalsidase Beta BS for Infusion "JCR" : Sales of 256 million yen (-39.9% YoY), based on supply plans to Sumitomo Pharma.
4. Contract Revenue and Other Income
   • Contract Revenue : 1,474 million yen (+1,278.8% YoY). Primarily driven by the receipt of consideration for the exercise of option rights under existing license agreements.
   • Other : 1,086 million yen (+359.9% YoY). Income related to business alliances and contract services expanded significantly.

---

3. Mid-to-Long-Term Growth Story: The Impact and Market Potential of the Blockbuster Drug "Givinostat"

The most anticipated growth driver for JCR Pharmaceuticals' future expansion is the Duchenne Muscular Dystrophy (DMD) treatment, "Givinostat."

(1) Unmet Medical Needs in DMD and the Positioning of Givinostat

DMD is a designated intractable disease characterized by muscle degeneration and necrosis due to dystrophin deficiency. Currently approved treatments in Japan (such as gene therapy or exon-skipping therapy) are highly limited by patient age or specific genetic mutations. In contrast, Givinostat , a histone deacetylase (HDAC) inhibitor, promotes muscle repair and suppresses fibrosis and fat replacement, offering the groundbreaking feature of being applicable to a wide range of DMD patients regardless of age or genetic mutation type.

(2) Domestic Development Schedule and Market Potential (Approx. 35 billion yen annual sales)

Regarding development, following consultations with the PMDA, the company aims to leverage overseas clinical data to file for manufacturing and marketing approval within 2026 , with the goal of obtaining approval and launching sales within 2027 .

The following slide shows the revenue growth opportunities Givinostat brings to the company.

[Slide Commentary: Importance of Revenue Growth Opportunities Driven by Givinostat]

This slide provides highly significant data visualizing the business impact once Givinostat is launched. Out of approximately 3,500 DMD patients in Japan, it is estimated that over 1,000 patients (ambulatory patients aged 6 and older) are eligible for treatment. Based on overseas treatment costs (approx. 50 million yen per year), it is estimated that reaching 70% of the target patient population would generate approximately 35 billion yen in domestic sales . Given that the company's current annual sales are in the 40–45 billion yen range, this single product holds the potential for a massive revenue impact, nearly equivalent to the company's existing consolidated sales.

Clinical data (EPIDYS study) also shows that adding Givinostat to standard care maintained walking ability for 2.9 years (hazard ratio 0.42), suggesting high demand in clinical settings.

---

4. Pipeline Expansion and Global Alliance Strategy

Leveraging its proprietary technology platform, including "J-Brain Cargo®," the company is advancing a diversified pipeline and strategic alliances.

• Global Expansion of Izcargo® (MENA Region) : In July 2026, the company obtained manufacturing and marketing approval in the United Arab Emirates (UAE) . Starting with this, the company plans to sequentially obtain approvals and launch sales in other MENA (Middle East and North Africa) countries through its distribution partner, Taiba.
• Progress of Key Development Pipelines
  • JR-141 (MPS II) : Global Phase 3 clinical trial is underway, aiming for approval in the US, Europe, and Brazil.
  • JR-401G (Growth Hormone Deficiency) : Domestic Phase 3 clinical trial is ongoing, allowing for dose adjustments based on patient treatment response.
  • JR-471 (Fucosidosis) : A global natural history study has begun to collect data for this ultra-rare disease, which affects fewer than 120 people worldwide.
• Alliance Building : Through partnerships with AstraZeneca Rare Disease (formerly Alexion), Angelini Pharma, and Medipal Holdings, the company is actively pursuing the out-licensing of platform technologies and joint development.

---

5. FY2027 Full-Year Earnings Forecast and Outlook

Although Q1 resulted in an operating loss due to upfront R&D investment, the company plans a significant return to profitability for the full year, driven by revenue growth and the recording of license income.

The following slide lists the consolidated earnings forecast for the fiscal year ending March 31, 2027.

[Slide Commentary: Significance of Full-Year Consolidated Earnings Forecast]

This slide outlines the path for the company to achieve a V-shaped recovery in performance for the full year based on Q1 progress:

• Net Sales : Planned at 45,700 million yen (+13.3% YoY). Specifically, contract revenue is expected to expand significantly to 8,100 million yen (+46.0% YoY), serving as a key profit driver.
• Operating Profit : Aiming for 1,100 million yen (+98.2% YoY), effectively doubling the profit from the previous year (555 million yen).
• R&D Expenses : While continuing record-level investment of 19,300 million yen for the full year (+15.1% YoY, or 24,300 million yen before deductions), the company plans to improve the operating profit margin to 2.6% (from 1.4% in the previous year) through revenue growth effects.

---

6. Conclusion and Comprehensive Assessment

JCR Pharmaceuticals' Q1 FY2027 results, while showing a short-term expansion in operating losses due to concentrated R&D investment, confirm that the expansion of its pipeline for mid-to-long-term growth is proceeding smoothly.

• Short-term Focus : The company is offsetting the impact of drug price revisions on "Growject®" through the expansion of Izcargo® cases and new contract revenue, continuing efforts to achieve 45.7 billion yen in sales and 1.1 billion yen in operating profit for the full year.
• Mid-to-Long-term Focus : "Givinostat," with its target of a 35 billion yen domestic market , is aiming for filing in 2026 and approval in 2027. Combined with the global rollout of Izcargo® in the MENA region, the company is entering a phase where the results of its global strategy will gradually become evident.

By leveraging its unique biotech platform and global partnership strategy, JCR Pharmaceuticals is expected to solidify its position in the rare disease field and further enhance its corporate value.